Friday 16 October 2026
Export AVXL’s income statement to Excel — free account
Anavex Life Sciences Corp.
AVXL Healthcare Biotechnology
In the quarter to June 2026, EPS grew 150.0% and free cash flow grew 27.0%, each against the same quarter a year earlier.
1.31
0.17
−11.49%
Follow AVXL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (12.80%) | (30.78%) | (33.63%) | (43.11%) |
+8 more TTM periods Free account |
|
| (11.70%) | (27.73%) | (31.08%) | (38.75%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(11.58%) | (28.01%) | (31.55%) | (48.89%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.32) | (0.35) | (0.38) | (0.46) | |
Free Cash Flow |
(29.29) | (32.66) | (34.07) | (39.04) | |
| Other line items | |||||
Cash ROIC |
(12.69%) | (13.11%) | (13.19%) | (19.77%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
2.25 | 0.96 | 0.85 | 0.84 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.32) | (0.35) | (0.38) | (0.46) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates